证券代码：688133 证券简称：泰坦科技 公告编号：2025-045 2025 年 11 月 29 日 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海泰坦科技股份有限公司（以下简称公司）于2025年8月20日召开第四届 董事会第十八次会议，于2025年9月5日召开2025年度第一次临时股东大会，审议 通过了《关于公司拟申请注册发行短期融资券的议案》。根据公司战略发展规划 及资金需求，公司拟向中国银行间市场交易商协会申请注册发行规模不超过1亿 元（含1亿元）的短期融资券（即科技创新债券）。具体内容详见公司于2025年8 月21日在指定媒体披露的《上海泰坦科技股份有限公司关于公司拟申请注册发行 短期融资券的公告》（公告编号：2025-030）。 公司已于近日完成了上海泰坦科技股份有限公司2025年度第一期科技创新 债券[债券简称：25泰坦科技CP001（科创债）]的发行。本期债券发行额为5,000.00 万元人民币，期限为365日，债券面值为人民币100.00元，发行利率为3.19%。本 期债券由上海农村商业银行股 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2025-044 上海泰坦科技股份有限公司 关于公司与关联方共同投资暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 上海泰坦科技股份有限公司（以下简称"泰坦科技"或"上市公司"或"公司"）和关联方上海泰坦合源一期 私募投资基金合伙企业（有限合伙）（以下简称"一期基金"）拟共同投资，对泰坦科技控股子公司上海 泰坦微源检测技术有限公司（以下简称"标的"或"微源检测"）进行增资。增资前，微源检测注册资本为 1000万元，泰坦科技100%持股；增资后，微源检测注册资本为5000万元，其中泰坦科技持股70%，一 期基金持股30%。微源检测新增的4000万元注册资本，泰坦科技认缴2500万元，一期基金认缴1500万 元，泰坦科技资金来源为自有资金。 ● 风险提示： 微源检测目前尚未开展业务，在未来的经营过程中，标的可能会面临行业变化、市场竞争、经营管理以 及不可抗力等风险，公司本次投资的收益具有不确定性，可能面临投资失败或者不达预期等情形。请各 位投 ...

（编辑 任世碧） 证券日报网讯 11月26日晚间，泰坦科技发布公告称，公司和关联方上海泰坦合源一期私募投资基金合 伙企业（有限合伙）（简称"一期基金"）拟共同投资，对泰坦科技控股子公司上海泰坦微源检测技术有 限公司（简称"标的"或"微源检测"）进行增资。增资前，微源检测注册资本为1000万元，泰坦科技 100%持股；增资后，微源检测注册资本为5000万元，其中泰坦科技持股70%，一期基金持股30%。微源 检测新增的4000万元注册资本，泰坦科技认缴2500万元，一期基金认缴1500万元，泰坦科技资金来源为 自有资金。本次投资系与关联方共同投资，构成关联交易。 ...

Group 1 - Aolide plans to raise no more than 300 million yuan through a simplified procedure for issuing shares to specific targets, with net proceeds allocated to the production base project for OLED display core materials and to supplement working capital [1] - Wanbang's subsidiary has obtained a 10-year exclusive agency for sildenafil oral suspension, which is suitable for patients with swallowing difficulties [2] - Titan Technology and its affiliate plan to jointly invest in increasing capital for its subsidiary, Micro Detection, raising its registered capital from 10 million yuan to 50 million yuan [3] Group 2 - Jindike will not issue new batches of quadrivalent influenza virus split vaccine this year, having produced approximately 1.56 million doses [4] - Aladdin intends to purchase 35% equity of Youke for 61.25 million yuan, funded by its own or raised capital [5] - Gujia Home's application for a private placement of A-shares has been approved by the Shanghai Stock Exchange [7] Group 3 - Honghe Technology's application for a private placement of A-shares has been approved by the China Securities Regulatory Commission [9] - Guangdian Yuntong has won contracts totaling 308 million yuan for the construction of an artificial intelligence application pilot base [10] - Shanghai Mechanical plans to repurchase B-shares worth no more than 278 million yuan [11] Group 4 - Weiling Co. is planning a change of control, with shares representing 7.76% of the total being transferred [14] - Jiugang Hongxing intends to invest 200 million yuan to establish a wholly-owned subsidiary focusing on high-quality special steel materials [16] - Zhongjian Technology has submitted an application for H-share listing [17] Group 5 - Sainuo Medical has received registration approval for its coronary product in Pakistan [18] - Huafeng Aluminum plans to acquire 100% equity of Huafeng Puen for 100 million yuan [20] - Fuda Co. intends to establish a wholly-owned subsidiary with an investment of 30 million yuan [22] Group 6 - Su Yan Jingshen's application for a private placement of shares has been approved by the Shanghai Stock Exchange [24] - Zhongchuang Co. has set the inquiry transfer price at 25.75 yuan per share [25] - Jinpu Garden has had a lawsuit involving 26.557 million yuan accepted by the court [29] Group 7 - ICBC has approved the appointment of Zhao Guid as vice president [30] - Betta Pharmaceuticals has had its drug registration application for ensartinib accepted [32] - Times New Materials plans to invest 6 million euros to establish a wholly-owned subsidiary in Serbia [34] Group 8 - China State Construction has appointed Chen Yong as vice president [36] - Dayang Electric plans to invest 10 million yuan to establish an industrial fund [38] - Advanced Digital has appointed Liu Zhigang as deputy general manager [39] Group 9 - Tianqi Co. plans to transfer 7% equity of Youqi Intelligent for 130 million yuan [40] - Xinguo has submitted an application for H-share issuance and listing [42] - Jinhongshun's shareholder has terminated a share reduction plan [43] Group 10 - Wanrun Co.'s actual controller plans to increase shareholding between 365 million yuan and 730 million yuan [44] - Suzhou High-tech plans to sell 47% equity of its medical device subsidiary for 604 million yuan [45] - Huayou Cobalt's subsidiary has signed a product supply agreement with Yiwei Lithium Energy for approximately 127,800 tons of materials [47] Group 11 - China Communications has won 10 important projects totaling approximately 2.539 billion yuan [49] - Nopushin plans to raise no more than 1.45 billion yuan through a private placement [50] - Yun Aluminum plans to acquire minority stakes in three subsidiaries for a total of 2.267 billion yuan [51] Group 12 - Xiamen Tungsten plans to establish a 500 million yuan merger fund with multiple parties [52] - Aotewei has signed a contract worth approximately 700 million yuan [54] - Hemai Co.'s shareholders plan to reduce their holdings by no more than 3% [56]

证券代码：688133 证券简称：泰坦科技 公告编号：2025-044 上海泰坦科技股份有限公司 关于公司与关联方共同投资暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 上海泰坦科技股份有限公司（以下简称"泰坦科技"或"上市公司"或"公 司"）和关联方上海泰坦合源一期私募投资基金合伙企业（有限合伙）（以下简 称"一期基金"）拟共同投资，对泰坦科技控股子公司上海泰坦微源检测技术有 限公司（以下简称"标的"或"微源检测"）进行增资。增资前，微源检测注册 资本为 1000 万元，泰坦科技 100%持股；增资后，微源检测注册资本为 5000 万元， 其中泰坦科技持股 70%，一期基金持股 30%。微源检测新增的 4000 万元注册资本， 泰坦科技认缴 2500 万元，一期基金认缴 1500 万元，泰坦科技资金来源为自有资 金。 本次投资系与关联方共同投资，构成关联交易，但不构成《上市公司重 大资产重组管理办法》规定的重大资产重组，交易实施亦不存在重大法律障碍。 至本次关联交易为止，过去 12 个月内 ...

格隆汇11月26日丨泰坦科技(688133.SH)公布，基于公司整体发展战略及业务需要的考虑，公司和关联 方一期基金拟共同投资，对微源检测进行增资。增资前，微源检测注册资本为1000万元，泰坦科技 100%持股；增资后，微源检测注册资本为5000万元，其中泰坦科技持股70%，一期基金持股30%。微源 检测新增的4000万元注册资本，泰坦科技认缴2500万元，一期基金认缴1500万元，泰坦科技资金来源为 自有资金。 微源检测成立于2025年2月，公司聚焦实验室服务三大核心板块：验证与检测服务、分析检测仪器设备 租赁及售后、分析检测设备关键零部件研发制造，公司旨在成为国内领先的独立生化实验室一站式综合 服务平台。微源检测目前尚未开展业务，运营初期依托泰坦科技的平台，由泰坦科技负责提供初始的技 术管理团队、行业资源、部分场地设备等支撑。未来随着业务的扩展，微源检测将形成独立的运营团 队、技术团队、ERP系统等，作为泰坦科技控股子公司独立经营发展。 ...

评级调低方面，11月17日至11月23日，券商调低上市公司评级达到7家次，最新数据包括了华创证券对太阳能的评 级从"强推"调低至"推荐"，西部证券对源杰科技的评级从"买入"调低至"增持"，华创证券对泰坦科技的评级从"强 推"调低至"推荐"。 | | | | 7家最新被调低评级的公司 | | | | --- | --- | --- | --- | --- | --- | | 证券代码 | 证券名称 | 机构 | 此前评级 | 最新评级 | 行业 | | 000591 | 太阳能 | 华创证券 | 强推 | 推荐 | 电力 | | 688498 | 源杰科技 | 西部证券 | 采入 | 増持 | 半导体 | | 688133 | 泰坦科技 | 华创证券 | 强推 | 推荐 | 化学制品 | | 000938 | 紫光股份 | 西部证券 | 买人 | 増持 | IT服务 | | 688232 | 新点软件 | 中泰证券 | 买人 | 増持 | 软件开发 | | 688056 | 菜伯泰科 | 华创证券 | 賀推 | 推荐 | 通用设备 | | 002541 | 鸿路钢构 | 华创证券 | 賀推 | 推荐 | 专业工 ...

Group 1 - The core viewpoint of the articles highlights significant changes in stock ratings and target prices for various companies, with notable increases for Wan Feng Ao Wei, Guang Xun Technology, and Tai Chen Guang [1] - Wan Feng Ao Wei's target price increased by 89.64%, Guang Xun Technology by 81.99%, and Tai Chen Guang by 71.51%, all within the automotive parts and communication equipment sectors [1] - A total of 408 companies received broker recommendations during the period, with Yili receiving 5 recommendations, and Top Group and United Imaging Medical receiving 4 each [1] Group 2 - Three companies had their ratings upgraded, including Huadong Heavy Machine from "Hold" to "Buy" by Caixin Securities, Sinopec from "Add" to "Buy" by Huatai Securities, and Hongyuan Electronics from "Add" to "Buy" by CITIC Securities [1] - Seven companies had their ratings downgraded, including Solar Energy from "Strong Buy" to "Recommended" by Huachuang Securities, Source Technology from "Buy" to "Add" by Western Securities, and Titan Technology from "Strong Buy" to "Recommended" by Huachuang Securities [1] - During the same period, 77 instances of first-time coverage were reported, with Delijia receiving an "Outperform" rating from Guosen Securities, and YTO Express, Yanjiang Co., and Far East Co. receiving "Add" or "Buy" ratings from various brokers [2]

Investment Rating - The report has downgraded the investment rating to "Recommendation" with a target price of 25.6 CNY, indicating a potential upside of 16% from the current price of 22.15 CNY [2][8]. Core Views - The company is experiencing revenue and profit pressure in Q3 2025, with a year-on-year revenue decline of 13.75% and a significant drop in net profit by 69.57% in the same quarter [2][8]. - Despite short-term performance challenges, the long-term outlook for the scientific services industry remains positive, with expectations of a recovery in downstream demand leading to a performance inflection point [8]. - The company is actively restructuring its business to focus on higher-margin operations, which has resulted in a slight improvement in gross margin to 22.15% [8]. Financial Summary - For the first three quarters of 2025, the company reported a total revenue of 1.848 billion CNY, down 13.06% year-on-year, while net profit attributable to shareholders was 11 million CNY, up 15.04% year-on-year [2][8]. - The projected revenues for 2025 to 2027 are 2.634 billion CNY, 2.812 billion CNY, and 3.072 billion CNY, respectively, with expected growth rates of -8.6%, 6.7%, and 9.2% [4][9]. - The net profit forecast for the same period is 16 million CNY, 36 million CNY, and 59 million CNY, with growth rates of 23.8%, 125.7%, and 64.4% respectively [4][9]. - The company has a current market capitalization of 3.642 billion CNY and a debt-to-equity ratio of 55.3% [5][9].

Company Overview - Titan Technology Co., Ltd. is located at 89 Shilong Road, Xuhui District, Shanghai, established on October 18, 2007, and listed on October 30, 2020 [1] - The company provides integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, smart laboratory equipment, research information technology, specialty chemicals, and related comprehensive technical services [1] - The revenue composition of Titan Technology is as follows: research reagents 42.70%, research instruments and consumables 28.42%, specialty chemicals 26.48%, laboratory construction and research information technology 2.37%, and others 0.02% [1] Financial Performance - As of September 30, Titan Technology reported a total revenue of 1.848 billion yuan for the period from January to September 2025, a year-on-year decrease of 13.06% [2] - The net profit attributable to the parent company was 11.1678 million yuan, reflecting a year-on-year increase of 15.04% [2] - Cumulative cash dividends since the A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3] Stock Performance - On November 20, Titan Technology's stock price decreased by 2.01%, trading at 22.92 yuan per share, with a total market capitalization of 3.769 billion yuan [1] - The stock has seen a year-to-date increase of 26.14%, but has declined by 7.99% over the last five trading days, 8.14% over the last 20 days, and 18.26% over the last 60 days [1] - As of the latest data, the number of shareholders is 9,293, an increase of 20.41% from the previous period, while the average circulating shares per person decreased by 16.95% to 17,694 shares [2] Market Activity - The net outflow of main funds was 4.5418 million yuan, with large orders buying 4.3981 million yuan (16.17% of total) and selling 8.9399 million yuan (32.87% of total) [1] - Titan Technology is categorized under the basic chemicals industry, specifically in the chemical products sector, and is associated with concepts such as buybacks, margin financing, pension concepts, scientific instruments, and electronic chemicals [1]